Reviewing Connect Biopharma (NASDAQ:CNTB) & Organogenesis (NASDAQ:ORGO)

Connect Biopharma (NASDAQ:CNTB) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Volatility and Risk

Connect Biopharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.

Institutional & Insider Ownership

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Connect Biopharma and Organogenesis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	8	0	2.78
Organogenesis	1	2	0	0	1.67

Connect Biopharma presently has a consensus price target of $5.88, suggesting a potential upside of 767.54%. Organogenesis has a consensus price target of $4.33, suggesting a potential upside of 434.91%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, research analysts plainly believe Connect Biopharma is more favorable than Organogenesis.

Profitability

This table compares Connect Biopharma and Organogenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Organogenesis	-39.34%	-55.28%	-23.72%

Valuation and Earnings

This table compares Connect Biopharma and Organogenesis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60,000.00	710.72	-$55.48 million	($1.19)	-0.57
Organogenesis	$564.17 million	0.19	$37.03 million	($1.22)	-0.66

Organogenesis has higher revenue and earnings than Connect Biopharma. Organogenesis is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Connect Biopharma beats Organogenesis on 9 of the 14 factors compared between the two stocks.

About Connect Biopharma

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

About Organogenesis

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.